0001104659-19-005523.txt : 20190204
0001104659-19-005523.hdr.sgml : 20190204
20190204160744
ACCESSION NUMBER: 0001104659-19-005523
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190204
DATE AS OF CHANGE: 20190204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gelone Steven P.
CENTRAL INDEX KEY: 0001693064
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 19563750
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
a4.xml
4
X0306
4
2019-01-31
0
0001641640
Nabriva Therapeutics plc
NBRV
0001693064
Gelone Steven P.
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
President & COO
Stock Options
2019-01-31
4
A
0
278400
0.00
A
2029-01-31
Ordinary Shares
278400
278400
D
Restricted Stock Units
2019-01-31
4
A
0
105750
0.00
A
2023-01-31
Ordinary Shares
105750
105750
D
The exercise price is $1.90 per share.
This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.
/s/ Robert Crotty, by power of attorney
2019-02-04